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Abstract: HDAC6 is an enzyme that regulates a variety of biological pathways in dividing 
cells, but also in post-mitotic neurons. In these cells, different cellular functions and survival 
are dependent on HDAC6-mediated processes such as intracellular trafficking, antioxidation, 
chaperone-mediated stress responses, and protein degradation. As a consequence, the interest 
in HDAC6 as a potential target to treat several neurodegenerative disorders has grown signifi-
cantly over the last decade. This review summarizes the current knowledge on the interaction 
partners and functions of HDAC6 as well as the most important arguments for its involvement 
in several neurodegenerative diseases. As many of these disorders are hallmarked by alterations 
in HDAC6-mediated pathways, it is hypothesized that HDAC6 could play a pivotal role in the 
pathophysiology of neurodegeneration. HDAC6-dependent deacetylation of its substrates could 
result in neurotoxicity, while the ubiquitin-dependent functions of HDAC6 could be essential 
for neuroprotection. Therefore, targeting the deacetylating activity of HDAC6, while leaving 
its other functions unhampered, might be an interesting strategy to treat neurodegenerative 
disorders.
Keywords: HDAC6, (de)acetylation, neurodegeneration, axonal transport, autophagy, 
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Introduction
Histone deacetylases (HDACs) are enzymes that play an important role in transcrip-
tional regulation by epigenetic modification of histones.1 Furthermore, some members 
of the HDAC family influence a variety of cellular processes through the modulation of 
non-histone substrates such as α-tubulin, ubiquitin, HSP90, cortactin, peroxiredoxins, 
and several transcription factors.2–7
The HDAC family consists of 18 members, subdivided into four groups. According 
to their sequence homology to the yeast Rpd3 protein, HDAC1, 2, 3, and 8 are catego-
rized as class I HDACs. These enzymes are ubiquitously expressed and localized in the 
nucleus, where they can influence transcription of genes.8 Class II HDACs, homologs 
of the yeast Hda1, show tissue-specific expression and are able to shuttle between the 
cytoplasm and the nucleus. They are further subdivided into class IIa (HDAC4, 5, 7, 
and 9) and IIb (HDAC6 and 10). Finally, HDAC11 is the only member of the class IV 
HDACs with similarities to the catalytic domains of both class I and II deacetylases.9 
Class I, II, and IV HDACs are also referred to as the conventional HDACs and 
require Zn2+ as a cofactor for their deacetylating activity.10 The nicotinamide adenine 
dinucleotide-dependent sirtuins 1–7 are another class of HDAC enzymes (class III) 
and are homologs of Sir2 in yeast.11
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Over the last decade, HDACs have been extensively 
studied for their role in cancer. Through histone deacetyla-
tion, the transcriptional regulation of tumor suppressor genes 
or oncogenes can be altered to influence the progression of 
cancer.12 As a consequence, HDAC inhibitors are a relatively 
new class of anticancer agents that induce cell cycle arrest 
and apoptosis in cancer cells and can reduce tumor growth.13 
Although there are multiple clinical trials ongoing with 
broad spectrum HDAC inhibitors, only a handful of class- 
or isoform-specific inhibitors are currently being tested in 
cancer-related studies. In general, HDAC inhibitors are well 
tolerated but some patients encountered adverse side effects 
such as nausea, thrombocytopenia, and fatigue.14 It is antici-
pated that isoform-specific inhibitors could have an improved 
efficacy and will be better tolerated during chronic treatment. 
From that perspective, the functions of specific subtypes of 
HDACs have been intensively studied and selective HDAC 
inhibitors are being developed.15
In particular, the interest in HDAC6 has grown over the 
past few years. It possesses some unique structural charac-
teristics compared to the other HDAC isoforms. HDAC6 has 
two functional N-terminal catalytic deacetylating domains, a 
C-terminal zinc finger ubiquitin-binding domain (ZnF-UBP) 
and a specific tetradecapeptide repeat domain (SE14) that, 
together with two leucine-rich nuclear export sequences, 
promotes its cytosolic retention.16 These unique features allow 
HDAC6 to interact with non-histone substrates of which 
α-tubulin, poly-ubiquitinated proteins, and HSP90 are the 
most studied ones.2,3,6 As such, HDAC6 can influence a wide 
range of cellular processes including cell growth, migration, 
and survival, but also protein degradation and intracellular 
trafficking. These latter processes are of pivotal importance 
for post-mitotic cells including neurons, which rely on effi-
cient protein degradation and axonal transport for normal 
functioning. As a consequence, HDAC6 has emerged as a 
potential target for the treatment of different types of cancer 
as well as several neurodegenerative disorders, including 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Hun-
tington’s disease (HD), and amyotrophic lateral sclerosis 
(ALS). This review will focus on the cellular functions of 
HDAC6 and its implications as a therapeutic target in differ-
ent neurodegenerative diseases.
The molecular functions of HDAC6
Regulation of microtubule dynamics  
by deacetylation of α-tubulin
Microtubules are cellular structures composed of α- and 
β-tubulin heterodimers that polymerize and depolymerize 
in a dynamic manner. Post-translational modifications of 
α-tubulin control these dynamics17,18 and influence cell 
division, cell–cell interactions, cell migration, and intracel-
lular trafficking.19 The discovery of α-tubulin as a substrate 
for HDAC6 improved the insights in microtubule dynamics 
and its biological significance. HDAC6 tightly regulates 
deacetylation of α-tubulin, which correlates to microtubule 
dynamics and proper functioning.20–22 Overexpression of 
HDAC6 completely deacetylates microtubules, while sup-
pression of HDAC6 function, either by pharmacological 
inhibition or by small interfering RNA, elevates the levels of 
acetylated α-tubulin, both in vitro and in vivo.20,22
Dynamic microtubules do not only orchestrate cell divi-
sion, cell differentiation, and motility in dividing cells,23 but 
they are also of vital importance in post-mitotic neurons.24 
These highly polarized cells require axonal transport of car-
gos from the cell body to the synapse and vice versa for nor-
mal cell function, neuronal plasticity, and survival. For this, 
neurons rely on the microtubule network, which functions as 
a track for molecular motors such as the kinesin and dynein 
superfamilies.25,26 Acetylation of α-tubulin improves the 
interaction between the motor protein kinesin-1 and micro-
tubules and promotes axonal trafficking.27 HDAC6 inhibition 
also improves the binding of kinesin-1 to α-tubulin28 and 
HDAC6 can directly bind to p150glued – a component of the 
dynein/dynactin motor complex.29 Indeed, knockdown of 
HDAC6 increases α-tubulin acetylation, the recruitment of 
kinesin-1 and dynein to microtubules, and enhances mito-
chondrial transport along the axon in cultured neurons.27,28,30 
In addition, other cellular pathways influence mitochondrial 
transport by regulating HDAC6 activity. For example, inhi-
bition of the GSK-3β signaling pathway decreases HDAC6 
activity, which in turn improves intracellular trafficking 
in hippocampal neurons.31 Taken together, HDAC6 can 
influence axonal transport, either directly by deacetylating 
α-tubulin or indirectly by binding to motor proteins. For these 
reasons, HDAC6-mediated deacetylation is thought to be an 
important regulator of axonal transport in neurons.
Regulation of the actin cytoskeleton  
by deacetylating cortactin
In addition to its role in microtubule-dependent processes, 
HDAC6 can also influence remodeling of the actin cytoskel-
eton through deacetylation of cortactin.4 After stimulation 
with growth factors, cortactin translocates to the membrane 
ruffles where it can bind F-actin to promote cell migration.4 
HDAC6 is also enriched in these membrane ruffles where it 
deacetylates cortactin. Overexpression of HDAC6 improves 
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the binding capacity of cortactin to F-actin and increases 
actin polymerization in vivo, whereas HDAC6 knockdown 
reduces cell motility.4
Regulation of the antioxidant  
reactivity through peroxiredoxins
Peroxiredoxins are antioxidants whose main function is to 
reduce H
2
O
2
 concentrations in cells.32 PRXI and PRXII have 
recently been added to the list of HDAC6 substrates. Under 
conditions of extreme oxidative stress, intracellular H
2
O
2
 
concentrations reach a critical threshold after which PRXI 
and PRXII oligomerize to high-molecular-weight complexes. 
After this transformation, peroxiredoxins lose their peroxi-
dase activity and function as molecular chaperones instead 
of antioxidants.33 Interestingly, high levels of acetylation 
improved the reducing activity as well as the resistance 
to oligomerization and overoxidation of PRXI and PRXII 
in vitro.7 Inhibition of the deacetylating function of HDAC6 
restores the peroxidase activity of PRXI and PRXII during 
periods of high oxidative stress.7 In conclusion, these results 
indicate that inhibition of HDAC6 can result in a beneficial 
increase of antioxidant reactivity of peroxiredoxins.
Regulation of the anti- 
inflammatory response
In health, the immune system is in perfect homeostasis. 
Upon infection or disease, the proinflammatory response 
is enhanced to eliminate toxic insults. Once the pathogen 
is cleared, anti-inflammatory signals temper that response 
in order to preserve the surrounding tissue. However, aber-
rant activation of the immune system can result in chronic 
inflammation, which is often observed in neurodegenerative 
disorders such as AD, PD, and ALS.34,35 Key regulators of 
inflammation are Foxp3-expressing regulatory T-cells. These 
cells reduce the expression of proinflammatory cytokines and 
suppress the activation of effector T-lymphocytes, thus tem-
pering immune reactions that are detrimental for the host and 
restoring immunological homeostasis.36 Recently, HDACs 
have been implicated as modulators of the immune response 
by promoting the expression of proinflammatory genes and 
HDAC inhibitors are emerging as anti-inflammatory agents.37 
Although it was suggested that the immunosuppressive effects 
were due to histone modification, HDAC6 has been shown to 
regulate the Foxp3+ regulatory T-cells through HSP90 
modulation.38 Genetic deletion or pharmacological inhibition 
of HDAC6 increased the suppressive activity of regulatory 
T-cells in models for autoimmunity and prevented allograft 
rejection.38 Since improving the regulatory T-cell function 
limits neuroinflammation,39,40 HDAC6 inhibitors could 
reduce chronic inflammation in autoimmune disorders and 
neurodegeneration.
Regulation of the chaperoning  
activity of HSP90
In 2005, HSP90 was identified as a substrate of HDAC6.3 
This molecular chaperone fulfills a pivotal role in diverse 
signaling pathways. It facilitates the maturation and assembly 
of transcription factors and other client proteins by improv-
ing their stability as well as their activity.41 It was shown 
that HDAC6 regulates the chaperone activity of HSP90 by 
reversible deacetylation.3 Furthermore, HSP90 binds to and 
regulates the activity of HSF1, a key enzyme in the response 
to cellular stress.42 As discussed in the section on autophagy, 
HDAC6 was identified as a component of a repressive com-
plex where it senses the presence of ubiquitinated aggregates 
and triggers the dissociation of this complex, activating 
a protective response to cytotoxic insults.43 As HDAC6 
regulates HSP90 activity, it most likely is a modifier of pro-
oncogenic pathways mediated by HSP90. Indeed, both HSP90 
inhibitors44 and HDAC6 inhibitors45 are useful as anticancer 
therapies by destabilizing the HDAC6–HSP90 interactions. 
Furthermore, a recent study reported that both HDAC6 
silencing and HSP90 knockdown in preclinical models of 
prostate cancer result in a downregulation of the androgen 
receptor and Akt expression, counteracting the resistance of 
tumor cells to hormone therapy.46 These results indicate that 
HDAC6 potentially modulates the function of other proteins 
by regulating HSP90 activity. In contrast to this, a recent 
study suggests that the positive effects of HDAC6 inhibition 
in prostate cancer cells correlates with cortactin-dependent 
cell motility rather than HSP90 regulation.47
Regulation of cellular pathways for 
protein-induced stress responses
Cells are able to cope with stress induced by abnormal 
proteins through a variety of pathways such as the ubiquitin-
proteasome system and autophagy (Figure 1).
The ubiquitin–proteasome system
The ubiquitin–proteasome system is the main cellular mecha-
nism for protein degradation. Misfolded or damaged proteins 
receive a poly-ubiquitin tag, after which they are directed to 
the proteasome for subsequent degradation.48 However, when 
the protein load is too high, the proteasome can become satu-
rated and cytotoxic aggregates will accumulate. In such cases, 
often observed in neurodegenerative disorders,49 cells must 
Research and Reports in Biology 2014:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4
van Helleputte et al
rely on alternative pathways to deal with protein-induced 
stress. The cytotoxic aggregates can then be cleared by 
chaperone-mediated autophagy or by macro-autophagy.
Autophagy
Degradation of proteins and organelles inside cellular inclu-
sions was first described by Christian de Duve in 1963.50 
This catabolic process is used for the recycling of cellular 
components to generate macromolecular building blocks and 
includes three different types: unselective micro-autophagy, 
macro-autophagy, and chaperone-mediated autophagy 
(Figure 1). In micro-autophagy, cytosolic components are 
directly engulfed by invagination of the lysosomal membrane 
for degradation. During macro-autophagy, also referred to 
as the endoplasmic reticulum-associated degradation path-
way, the cytosolic substrates are surrounded by a double 
membrane, which initiates primarily from the endoplasmic 
reticulum, forming the autophagosome. In later stages, 
this structure fuses with lysosomes and subsequently the 
substrates are degraded.51 Unlike conventional micro- and 
macro-autophagy, chaperone-mediated autophagy does 
not require the formation of autophagosomes. Instead, the 
substrates contain a consensus sequence that is recognized 
by Hsc70, after which Hsc70 and its co-chaperones form 
a complex and interact with LAMP-2A. This interaction 
is followed by direct translocation of the substrates across 
the membrane to the lysosomal lumen for subsequent 
degradation.52 Interestingly, HDAC6 has been reported to 
play a role at different levels in these processes that cope 
with cytotoxic aggregates.43
First of all and due to the high-affinity binding of HDAC6 
to ubiquitin, it was suggested that chaperones are involved 
in the regulation of the ubiquitin-dependent functions of 
HDAC6.53 A beacon molecule in the degradation pathway is 
the chaperone-like 97 kDa VCP/p97. This adenosine triphos-
phatase associated with diverse cellular activities plays a 
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Figure 1 The role of HDAC6 in multiple degradation pathways of the cell.
Notes: (i) UPS: under physiological conditions, abnormal and misfolded proteins are degraded through the UPS. First, these proteins receive a poly-ubiquitin tag via a multistep 
pathway involving several ligases and conjugation enzymes (e1–e3). Next, vCP/p97, currently dominating in the vCP/p97–HDAC6 complex, dissociates ubiquitinated proteins 
from HDAC6 and activates the UPS. Substrates will then be transported to the proteasome for degradation. (ii) Macro-autophagy: under pathological conditions, the UPS 
system can be saturated or dysfunctional. in such cases, cells rely on the aggresome and/or macro-autophagy for the degradation of cytosolic components to provide cells 
with necessary building blocks and reduce cellular stress. when ubiquitinated proteins accumulate, the vCP/p97–HDAC6 balance will shift in favor of HDAC6. Next, 
HDAC6 couples the aggregates to the motor protein complex for retrograde transport. in the perinuclear region, these accumulating proteins form the aggresome, which 
will be engulfed by a double membrane together with other cytosolic components (eg, mitochondria), to form an autophagosome. HDAC6 further mediates the maturation 
of the autophagosome and promotes their fusion with the lysosome, where the content will be degraded. (iii) CMA: under stress, cells will activate a pathway called the 
heat shock response. HDAC6 forms a complex with the chaperone HSP90 and the transcription factor HSF1. After detecting ubiquitinated proteins, HDAC6 mediated the 
dissociation of the complex, resulting in the release and activation of HSF1. This will promote the transcription of different heat shock proteins and co-chaperones. These 
factors will form a complex that can recognize proteins and delivers them to the lysosome via LAMP-2A. (iv) Micro-autophagy: the last form of autophagy is micro-autophagy. 
HDAC6 promotes the maturation of lysosomes, which can then engulf cytosolic components directly by invagination. in contrast to macro-autophagy, the formation of 
autophagosomes is not required.
Abbreviations: CMA, chaperone-mediated autophagy; UPS, ubiquitin–proteasome system.
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pivotal role in the targeting of poly-ubiquitinated proteins to 
the proteasome, a process that can be subdivided into three 
steps. First, substrates that require degradation have to be 
recognized, which is mediated by the ubiquitin conjugation 
system. Second, poly-ubiquitinated proteins are translocated. 
Finally, these proteins are degraded by the 26S proteasome.54 
VCP/p97 governs critical steps in this process such as retro-
translocation and transportation of ubiquitinated proteins 
to the proteasome.55 The interaction between VCP/p97 and 
HDAC6 is important in the decision whether ubiquitinated 
proteins are cleared by proteasome-mediated degradation or 
by macro-autophagy. Indeed, it was shown that VCP/p97 
interacts with HDAC6 and can exert its segregase activity 
to release HDAC6 from ubiquitinated proteins, favoring 
proteasomal clearance (Figure 1).56 However, when excess 
proteins accumulate and aggregate, the VCP/p97–HDAC6 
balance will shift. This can be due to a decrease in VCP/p97 
levels, an increase in HDAC6 expression, or both. It allows 
HDAC6 to mediate protein delivery to the dynein/dynactin 
motor complex for retrograde transport and induce the for-
mation of an inclusion body, also known as the aggresome.57 
These data indicate that HDAC6 does not only link protein 
ubiquitination to the proteasome, but also to the cytoskeleton-
dependent degradation and autophagy.6
Second, HDAC6 interacts with HSP90 and regulates its 
chaperone activity as mentioned above.3 Together with HSF1 
and HSP90, HDAC6 forms a complex in which HSF1 is 
maintained in an inactive form by HSP90. HDAC6-mediated 
detachment of the HSP90/HSF1 complex is required for 
activation of the heat shock response. It was suggested that 
HDAC6 forms a bridge between protein-induced stress and 
activation of this pathway in neurons that are continuously 
exposed to toxic insults during the course of disease.43 After 
detecting the presence of ubiquitinated proteins, HDAC6 will 
deacetylate HSP90, promoting dissociation of the HDAC6/
HSP90/HSF1 complex and stimulating a heat shock response. 
Heat shock proteins are known to associate with ubiquitinated 
proteins, to induce chaperone-mediated autophagy, and to 
prevent the formation of cytotoxic aggregates.58 In addition to 
its well-known role in malignancies, HSP90 is also important 
for maintaining the stability of neuronal proteins associated 
with neurodegenerative disorders, which could promote the 
accumulation of toxic aggregates.59 As a consequence, modu-
lation of HDAC6 activity could be a therapeutic strategy in 
neurodegeneration.
Third, a study from Pandey et al suggested that autophagy 
compensates for proteasome deficiency in an HDAC6-
dependent manner.60 Although HDAC6 is not essential for 
autophagy activation per se, it seems to be implicated in 
the maturation of lysosomes and their subsequent fusion 
with autophagosomes.61 The molecular determinants for the 
formation of autophagic vacuoles and maturation of these 
autophagosomes are called Atg proteins.62 Lysosomes and 
Atg proteins are recruited to the perinuclear aggresome by 
a process that requires HDAC6.61 In fact, loss of HDAC6 
impairs the recruitment of lysosomes and LC3, a well 
established indicator for autophagic processing, to the 
aggresome.63 Furthermore, the F-actin cytoskeleton is also 
essential in autophagosome–lysosomal fusion.64 F-actin 
remodeling is regulated through reversible deacetylation of 
cortactin and is thus controlled by HDAC6.4
In conclusion, HDAC6 is required for 1) retrograde 
transport of ubiquitinated aggregates – functioning as a 
bridge between ubiquitin and the dynein/dynactin motor 
complex, 2) formation of the aggresome, and 3) fusion of 
autophagosomes with lysosomes through modulation of the 
F-actin cytoskeleton.43,63–65
Stress granules
HDAC6 has been associated with stress granules –  cytoplasmic 
structures in which a reversible block of messenger RNA 
(mRNA) translation occurs after cellular stress.66 Dysfunction 
of the proteasome does not only induce autophagy but also 
an increased formation of stress granules.67 Intriguingly, 
HDAC6 co-localizes with stress granules and interacts with 
G3BP – another stress granule protein.68 Phosphorylation of 
G3BP reduces the interaction with HDAC6 and decreases 
the formation of stress granules. Furthermore, disruption of 
the microtubules or the dynein/dynactin motor complex, as 
well as pharmacological or genetic inhibition of HDAC6, 
abolishes the formation of stress granules.68 These results 
indicate a modulatory role for HDAC6 in both autophagy and 
the formation of stress granules after cellular stress.
Conclusions on HDAC6 mechanisms
In summary, HDAC6 functions as an important regulator in 
a variety of biological pathways in dividing cells, but also in 
post-mitotic neurons. In these cells, survival is more depen-
dent on HDAC6-mediated processes such as intracellular traf-
ficking, antioxidation, chaperone-mediated stress responses, 
and protein degradation.7,28,43,65 Over the last decade, interest 
in the role of HDAC6 in disease has grown significantly, 
especially its role in cancer (reviewed in Aldana-Masangkay 
and Sakamoto69) and in neurodegeneration (discussed in the 
next part of this review in which we highlight the key role of 
HDAC6 in neurodegeneration). In neurons, it was suggested 
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that HDAC6 plays a dual role as it balances between 
neuroprotection and neurodegeneration.9 HDAC6-dependent 
deacetylation of its substrates can shift the balance towards 
neurotoxic insults, whereas the ubiquitin-dependent activities 
of HDAC6 promote neuroprotection. As a consequence, the 
use of compounds that specifically inhibit the deacetylat-
ing activity of HDAC6, while leaving its functions in stress 
response and protein degradation unaltered, might be the 
treatment of choice for several diseases, including neurode-
generative disorders. Several HDAC6-specific inhibitors with 
improved brain permeability are being developed, enhancing 
their therapeutic potential in neurodegeneration.70 To date, 
only one HDAC6 inhibitor (ACY-1215) is being tested in a 
clinical trial for multiple myeloma.71 The bioavailability in 
the central nervous system has not been studied in humans 
so far, but it would be interesting to evaluate its potential for 
clinical use in neurological disorders.
HDAC6 as a key player  
in neurodegeneration
AD, PD, HD, ALS, spinal muscular atrophy (SMA), and 
Charcot–Marie–Tooth disease (CMT) are well known 
examples of neurodegenerative disorders. These diseases 
have some pathophysiological hallmarks in common. 
These include amongst others: dysfunctional mitochondria, 
reduced axonal transport, abnormal aggregation of misfolded 
proteins, and increased oxidative stress.72–75 Intriguingly, 
HDAC6 fulfills a regulatory role in many of these processes 
as discussed in the first part of this review on the molecular 
functions of HDAC6. This part of the review summarizes the 
available information on HDAC6 involvement in different 
neurodegenerative disorders (Table 1).
AD
AD is the most common form of dementia characterized by 
the deposition of amyloid-β
42
 plaques and neurofibrillary 
tau tangles. This leads to neuronal loss in specific areas of 
the brain. Abnormal tau phosphorylation and subsequent 
accumulation of neurofibrillary tau tangles was proposed to 
compromise microtubule dynamics and neuronal function.76 
As HDAC6 directly binds to tau, both in vitro and in vivo, 
and influences the phosphorylation and incorporation of tau 
into neurofibrillary tau tangles, it is a potential modifier of 
AD pathology.77,78 A positive correlation between HDAC6 
and tau burden was reported as a loss of HDAC6 function 
or expression attenuates the phosphorylation of tau and 
promotes its clearance.77,79 This was confirmed in a mouse 
model for AD treated with two different HDAC6 inhibitors.80 
More recently, it was confirmed that HDAC6 inhibition 
or deficiency modulates tau acetylation, phosphorylation, 
and isoform expression in oligodendrocytes,81 emphasizing 
the link between HDAC6 and AD. Furthermore, HDAC6 
expression is upregulated in hippocampal neurons exposed 
to amyloid-β plaques in vitro,82 in the brain of a mouse 
model for AD,82 and in the hippocampus of AD patients.77,83 
A recent study found similar HDAC6 levels in the temporal 
neocortex of AD patients and controls,84 indicating that the 
increase in HDAC6 expression is limited to hippocampal 
neurons, especially those with a high tau burden. These 
studies suggest an HDAC6-mediated compensatory response 
to stress. Unexpectedly, another study found an increase in 
the acetylation level of α-tubulin in the same brain region of 
AD patients in combination with an upregulation of HDAC6 
expression.83,85 This discrepancy might be explained by the 
fact that tau directly inhibits HDAC6 function.83 It could be 
that neurons activate a compensatory increase in HDAC6 
expression to deal with the protein stress following the accu-
mulation of amyloid-β and tau. However, the excess tau can 
directly inhibit the function of the HDAC6 protein resulting 
in increased α-tubulin acetylation.77,83
Despite these conflicting results, the potential use of HDAC6 
inhibitors as a treatment for AD was emphasized by two inde-
pendent studies in which it was shown that specific HDAC6 
inhibition can rescue the deficits in mitochondrial transport 
induced by amyloid-β toxicity in hippocampal neurons.28,82 
Similarly, inhibition of the deacetylase activity of HDAC6 
restores tau-induced microtubule defects in  Drosophila86 and 
cognitive defects in AD mice.87 The finding that reducing endog-
enous HDAC6 ameliorates cognitive deficits in a mouse model 
for AD by restoring α-tubulin acetylation and mitochondrial 
trafficking88 further strengthens the potential of HDAC6 as a 
suitable therapeutic target in AD.
Taken together, these studies imply both a protective 
and a detrimental role of HDAC6 in the pathophysiology of 
AD. Although this may seem counterintuitive, the apparent 
paradox could be explained by the dual function of HDAC6 
in AD. On one hand, HDAC6 is recruited to accumulating 
aggregates. Next, HDAC6 binds these ubiquitinated aggre-
gates and couples them to the dynein/dynactin motor complex 
to promote their transport and inclusion in the aggresome, 
followed by the degradation of these cytotoxic aggregates. 
This ubiquitin-dependent function of HDAC6 could be ben-
eficial and promote neuronal survival. On the other hand, 
HDAC6 can increase neuronal stress by deacetylating tau. 
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Acetylation and phosphorylation of tau occurs on the same 
motif and HDAC6-mediated deacetylation of tau renders 
this motif available for phosphorylation.78 Whereas acetyla-
tion would prevent the aggregation and increase the clear-
ance of tau, phosphorylation promotes the formation of 
neurofibrillary tau tangles. In accordance with this, it was 
reported that these motifs are hypoacetylated in AD patients, 
leading to increased neuronal stress.78 As a consequence, 
inhibiting the deacetylase activity of HDAC6, while leav-
ing its role in protein degradation unhampered, could be an 
interesting strategy to treat AD.
PD
PD is the second most common neurodegenerative disease, 
caused by a selective loss of dopaminergic neurons in 
the substantia nigra. Although neuronal death is mainly 
idiopathic, aberrant protein aggregation is most likely the 
key factor in the development of PD as neuronal lesions 
are accompanied by aggresome-like inclusion bodies, 
called Lewy bodies.89 Furthermore, Lewy bodies sequester 
ubiquitin-activating enzyme E1 and Hsp70, two enzymes 
that are recruited to the aggresome in the HDAC6-mediated 
response to protein stress.6 The importance of HDAC6 in PD 
Table 1 The role of HDAC6 in different neurodegenerative diseases
Disease HDAC6 in patients Role of HDAC6 References
Alzheimer’s disease increased in  
hippocampus77,83
Positive
-  Reduces protein stress induced by amyloid-β and NFTs via the aggresome
Negative
77–79,81,86
-  Promotes phosphorylation of tau and formation of NFTs
-  Disturbs axonal transport of mitochondria in mice and Drosophila
-  inhibition of HDAC6 restores cognitive defects in Alzheimer disease mice
77–80  
28,82,86,88 
80,87,88
Parkinson’s disease Unknown Positive
-  Reduces protein stress induced by α-synuclein via Lewy bodies and aggresome 
formation
-  Protects dopaminergic neurons in Drosophila
-  Promotes clearance of dysfunctional mitochondria
90–92 
 
91 
93
Huntington’s disease Unknown Positive
Note: reduced  
α-tubulin acetylation  
in striatum30
-  Reduces protein stress by aggregated Htt
Negative
-  Disturbs axonal transport of BDNF
63 
 
30
Amyotrophic lateral 
sclerosis
Unknown 
Note: increased GFAP  
acetylation in spinal  
cord astrocytes108
Positive
-  Reduces protein stress by mutant SOD1
-  Promotes stress granule formation and neurite outgrowth
Negative
-  Genetic deletion delays disease progression in mutant SOD1 mice
-  HDAC inhibition protects against motor neuron death and axonal degeneration
 
104 
68,98
 
102 
103
Spinal muscular  
atrophy
Unknown Positive
-  Promotes expression of full-length SMN2 by sequestering aberrantly spliced  
SMN in the aggresome
-  Ameliorates neurodegenerative phenotype in Drosophila
Negative
-  Reduces axonal transport in sciatic nerve of SMNΔ7 mice
 
112 
 
60 
 
114
Charcot–Marie– 
Tooth disease
Unknown Positive
-  Reduces protein stress by induction of aggresome–autophagy pathway
Negative
 
119,121,122
-  Blocks axonal transport of mitochondria via deacetylating α-tubulin
-  Pharmacological inhibition rescues phenotype in mutant HSPB1 mice
123 
123
Common hallmarks Positive – ubiquitin-dependent functions
-  Promotes protein degradation via the aggresome-autophagy pathways
-  Promotes chaperone-mediated stress response
-  Promotes formation of stress granules
Negative – deacetylase-dependent functions
-  Disturbs axonal transport by deacetylating α-tubulin
-  Disturbs actin cytoskeleton by deacetylating cortactin
-  Reduces antioxidant capacity by deacetylating  peroxiredoxins
Abbreviations: BDNF, brain-derived neurotrophic factor; NFT, neurofibrillary tangle; SOD1, superoxide dismutase 1.
Research and Reports in Biology 2014:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
8
van Helleputte et al
is emphasized by a study demonstrating the co-localization 
of HDAC6 with α-synuclein – a genetic cause of familial PD 
– inside the Lewy bodies in brain sections of PD patients.44 
Recently, it was suggested that HDAC6-mediated protein 
degradation is protective in PD and dementia with Lewy 
bodies.90 In this study, overexpression of mutant α-synuclein 
or 1-methyl-4-phenylpyridinium-induced neuronal stress 
significantly increases HDAC6 expression in PC-12 cells.90 
Likewise, HDAC6 inhibition reduces the autophagic 
response and the formation of Lewy bodies, followed by an 
impaired clearance of mutant α-synuclein.90 The protective 
nature of HDAC6 was confirmed by a study in Drosophila 
in which the endogenous Hdac6 protects dopaminergic neu-
rons against cytotoxic α-synuclein aggregates by stimulat-
ing aggresome-like inclusion formation.91 Moreover, the E3 
ligase parkin, mutated in autosomal recessive PD, mediates 
the polyubiquitination of DJ-1, which serves as a signal 
for HDAC6 to promote the sequestration of ubiquitinated 
aggregates into the aggresome.92 Parkin also mediates 
HDAC6-dependent mitophagy. After ubiquitination of dys-
functional mitochondria by parkin, the autophagic mediators 
HDAC6 and p62 are recruited and mitochondrial clearance 
is enhanced.93 Taken together, these results are in favor of 
a neuroprotective role of HDAC6 and for the potential use 
of HDAC6 agonists as a therapeutic strategy in PD. So far, 
no HDAC6 agonists have been studied.
HD
HD is a neurodegenerative disease elicited by an abnormal 
polyglutamine expansion in the huntingtin protein. HD 
patients display defects in motor coordination (chorea) and 
cognitive function. It was suggested that polyglutamine 
proteins cause neuronal dysfunction in Drosophila by 
two mechanisms: accumulation of aggregated huntingtin 
and disturbances in axonal transport.94 Although it was 
originally thought that these mechanisms were independent, 
HDAC6 is now associated with both processes.6,27 Indeed, 
HDAC6-dependent retrograde transport mediates clearance 
of aggregated huntingtin in neuronal cells,63 while HDAC6 
inhibition increases α-tubulin acetylation and restores 
axonal transport of vesicles containing BDNF.30 Moreover, 
brains of HD patients show a significant reduction in acety-
lated α-tubulin.30 These data suggest that HDAC6 could 
be a good therapeutic target. However, the use of HDAC6 
inhibitors to treat HD is still under  discussion. Bobrowska 
et al showed that HDAC6 knockout is not able to modify 
disease progression in a mouse model of HD, although 
α-tubulin acetylation increases.95 Another study observed 
improvements of the neurodegenerative phenotype in the 
same mouse model after inhibition of SIRT2, another tubulin 
deacetylating enzyme belonging to the class III HDACs.96 
As a consequence, the potential of HDAC6 as a therapeutic 
target to treat HD needs to be further investigated.
ALS
ALS is a fatal neurodegenerative motor neuron disease char-
acterized by the selective loss of motor neurons in the spinal 
cord, brainstem, and motor cortex. This results in progressive 
muscle atrophy and paralysis. Most patients decease within 
5 years after diagnosis due to respiratory failure. Familial 
cases of ALS have been associated with mutations in Tar 
DNA binding protein 43 (TDP-43) and fused in sarcoma/
translocated in sacroma (FUS/TLS), two RNA-binding pro-
teins that co-localize with HDAC6 in stress granules.68 In 
fact, TDP-43 and FUS/TLS are both essential components 
of a complex that regulates HDAC6 mRNA.97 TDP-43 
knockdown negatively influences HDAC6 expression, which 
results in decreased neurite outgrowth of human neuroblas-
toma cells.98 The finding that ALS-causing mutations in 
TDP-43 impair the microtubule-dependent axonal transport 
of mRNAs99 further supports the assumption that HDAC6 
could be involved in ALS. In addition, mutations in VCP/p97 
are also associated with ALS100 and the link between VCP/
p97 and HDAC6, both orchestrating the fate of ubiquitinated 
proteins, is well established.53 As ubiquitin-positive aggre-
gates are present in several mouse models as well as in ALS 
patients,101 HDAC6 could be implicated in ALS pathogenesis. 
Some evidence was found supporting this notion as genetic 
deletion of Hdac6 delays disease progression and increases 
survival in the mutant SOD1G93A mouse model for ALS.102 
In addition, treatment of symptomatic SOD1G93A mice with 
a general HDAC inhibitor, trichostatin A, protects against 
motor neuron death and axonal degeneration.103 Moreover, 
it was suggested that HDAC6 is directly involved in aggre-
gation and turnover of mutant SOD1 in the same mouse 
model.104 Furthermore, mutations in ubiquilin-2 (UBQLN-2) 
cause familial ALS and are observed in spinal cord neuronal 
inclusions of ALS patients.105 UBQLN-2 functionally links 
the ubiquitination pathway with the ubiquitin–proteasome 
system to promote in vivo protein degradation,105 highlight-
ing the importance of the autophagy pathway in ALS with a 
possible role for HDAC6. De Zoeten et al found that inhibi-
tion of HDAC6 improves the function of Foxp3+ regulatory 
T-cells,38 which could in theory reduce neuroinflammation 
and disease progression in ALS mice.106,107 Additionally, a 
proteomic analysis found differences in protein acetylation 
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in the post-mortem spinal cords between ALS and non-ALS 
subjects, suggesting that HDAC6 activity is altered during 
disease.108 Altogether, these observations indicate a potential 
role for HDAC6 in ALS.
SMA
SMA is the most common fatal neuromuscular disease in 
infants and is in most cases caused by mutations in the gene 
encoding SMN. A nearly identical gene copy (SMN2) is 
still present in these patients, but is unable to protect from 
disease due to aberrant splicing of exon 7. Insufficient levels 
of the SMN protein cause α-motor neuron death and eventu-
ally patients will suffer from fatal respiratory deficiencies. 
To date, no effective cure is available although activat-
ing SMN2 expression is a popular strategy in preclinical 
studies.109,110 It was shown that inhibition of HDACs could 
increase SMN protein levels in vitro and in vivo109 and could 
improve the survival of a mouse model for SMA.110 Valproic 
acid, an antiepileptic drug with HDAC inhibitory effects, 
is currently tested in a clinical trial in children with SMA 
(NCT01671384). Although the positive effects most likely 
result from histone modification, a potential role for HDAC6 
in SMA has also been proposed.111 Sequestering aberrantly 
spliced SMN2 in inclusion bodies would promote expression 
of full-length SMN2, thus increasing functional SMN protein 
levels.112 As a consequence, HDAC6 might be important in 
the pathophysiology of SMA due to its role in the formation 
of the aggresome and stress granules. Furthermore, Pandey 
et al found that HDAC6 overexpression ameliorated the neu-
rodegenerative phenotype in a Drosophila model for SMA.60 
Although there is still some controversy on the presence of 
axonal transport deficits in SMA, the influence of HDAC6 on 
microtubule dynamics could also play a role in SMA. While 
one study failed to detect defects of intracellular trafficking in 
cultured embryonic motor neurons from a mouse model for 
SMA,113 another group discovered a reduction in fast axonal 
transport in the sciatic nerve of symptomatic SMA∆7 mice.114 
Nevertheless, it would be interesting to evaluate whether 
inhibition of the α-tubulin deacetylating activity of HDAC6 
could restore axonal transport, prevent motor neuron death, 
and improve the SMA phenotype.
CMT
CMT is the most common non-lethal hereditary disease of 
the peripheral nervous system with more than 70 associ-
ated genes identified so far.115 Clinical symptoms include 
progressive muscle wasting that starts distally (“stocking–
glove” pattern), foot and hand deformities, sensory deficits, 
and steppage gait. A variety of animal models were created 
based on the identification of CMT-causing genes. Remark-
ably, several of these models show a similar pathophysiology 
with deficits in axonal transport,116–118 aggregation of mutated 
proteins,119,120 and altered protein degradation by the protea-
some and aggresome–autophagy pathway.119,121,122 Evidence 
was found for a role of HDAC6 in the pathophysiology 
of CMT.123 A mutant HSPB1-induced CMT mouse model 
was created, recapitulating the clinical features observed 
in patients and with a reduction in acetylated α-tubulin. 
Moreover, cultured dorsal root ganglion neurons show severe 
defects in axonal transport.123 Pharmacological inhibition of 
the deacetylating activity of HDAC6 rescues the phenotype 
of mutant HSPB1-expressing mice, both at the cellular and 
the behavioral level.123 As a consequence, HDAC6 is a good 
therapeutic target in CMT.
Conclusions
These different studies provide strong evidence that 
HDACs, and in particular HDAC6, are important in a 
wide range of neurodegenerative disorders. Moreover, 
HDAC6 might be the common link through its regulatory 
function in the stress response, protein degradation, and 
axonal transport –  different processes that are all altered 
in the above mentioned diseases. Altogether, it appears that 
HDAC6 has both neuroprotective and neurodegenerative 
properties. In neurodegenerative disorders, ubiquitinated 
aggregates accumulate during the course of the disease 
and increase the cellular burden. Subsequently, stress-
induced cellular responses will target these aggregates 
to the proteasome for degradation. The increased protein 
load will eventually saturate this first line of defense and 
HDAC6 could be recruited to the accumulating ubiquit-
inated  proteins. Through its interaction with VCP/p97 and 
ubiquitin, HDAC6 favors protein degradation by alternative 
pathways such as aggresome formation and autophagy. 
HDAC6 facilitates the delivery of ubiquitinated proteins to 
the aggresome by recruiting the motor protein dynein, which 
transports the aggregates to the perinuclear region, thus pro-
moting their clearance. Simultaneously, HDAC6 will recruit 
components of the autophagic machinery and stimulate the 
autophagosome–lysosomal fusion. Finally, HDAC6 will 
contribute to the formation of stress granules to ensure the 
conservation of untranslated mRNAs during cellular stress. 
All together, these cellular effects emphasize the neuropro-
tective nature of HDAC6. However, as HDAC6 is recruited 
to ubiquitinated aggregates, it may also cause excessive 
deacetylation of its substrates, generating an accumulation 
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of neurotoxic insults. For example, increased deacetylation 
of α-tubulin or  cortactin can disturb the microtubule and 
actin dynamics, which affect the cytoskeletal structure in 
neurons. Furthermore, the recruitment and anchoring of 
motor  proteins to the microtubules is reduced following 
deacetylation of α-tubulin. Moreover, HDAC6-mediated 
deacetylation of peroxiredoxins will increase oxidative 
stress, eventually contributing to neurodegeneration.
In conclusion, specific inhibition of the deacetylating 
function with specific inhibitors could be a good strategy to 
eliminate the negative aspects of HDAC6, while leaving its 
protective role in the stress response and protein degradation 
unhampered. As a consequence, the authors believe that this 
could be a good therapeutic approach in different forms of 
neurodegeneration.
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